CN110612127A - 预防口腔癌的方法 - Google Patents

预防口腔癌的方法 Download PDF

Info

Publication number
CN110612127A
CN110612127A CN201880031117.2A CN201880031117A CN110612127A CN 110612127 A CN110612127 A CN 110612127A CN 201880031117 A CN201880031117 A CN 201880031117A CN 110612127 A CN110612127 A CN 110612127A
Authority
CN
China
Prior art keywords
mir
oral
leukoplakia
oral cancer
exosomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880031117.2A
Other languages
English (en)
Other versions
CN110612127B (zh
Inventor
周宇
关晓兵
陈莉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Stomatological Hospital
Original Assignee
Beijing Jieteng Biological Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Jieteng Biological Technology Co ltd filed Critical Beijing Jieteng Biological Technology Co ltd
Publication of CN110612127A publication Critical patent/CN110612127A/zh
Application granted granted Critical
Publication of CN110612127B publication Critical patent/CN110612127B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

携带miR‑185的外泌体预防和治疗口腔癌的方法，以及包含经过改造的唾液外泌体的、用于预防和治疗口腔癌的药物组合物。

Description

PCT国内申请，说明书已公开。

Claims (27)

  1. PCT国内申请，权利要求书已公开。
CN201880031117.2A 2017-05-11 2018-05-10 预防口腔癌的方法 Active CN110612127B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710330847 2017-05-11
CN201710330847X 2017-05-11
PCT/CN2018/086347 WO2018205978A1 (zh) 2017-05-11 2018-05-10 预防口腔癌的方法

Publications (2)

Publication Number Publication Date
CN110612127A true CN110612127A (zh) 2019-12-24
CN110612127B CN110612127B (zh) 2023-03-31

Family

ID=64104671

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880031117.2A Active CN110612127B (zh) 2017-05-11 2018-05-10 预防口腔癌的方法
CN201810444172.6A Pending CN108853131A (zh) 2017-05-11 2018-05-10 携带miR-185的外泌体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810444172.6A Pending CN108853131A (zh) 2017-05-11 2018-05-10 携带miR-185的外泌体及其用途

Country Status (3)

Country Link
US (2) US20200268785A1 (zh)
CN (2) CN110612127B (zh)
WO (1) WO2018205978A1 (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029903A1 (en) * 2009-09-10 2011-03-17 Flemming Velin Method for the preparation of micro-rna and its therapeutic application

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029903A1 (en) * 2009-09-10 2011-03-17 Flemming Velin Method for the preparation of micro-rna and its therapeutic application

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
T SASAHIRA ET AL.: "Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer.", 《BR J CANCER.》 *
TARA L JOHNSON ET AL.: "Inhibition of Cell Proliferation and MAP Kinase and Akt Pathways in Oral Squamous cell Carcinoma by Genistein and Biochanin A.", 《EVID BASED COMPLEMENT ALTERNAT MED.》 *
XIN MA ET AL.: "MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma.", 《UROL ONCOL.》 *
YUKARI TAKAHASHI ET AL.: "MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines.", 《PLOS ONE.》 *

Also Published As

Publication number Publication date
US20220016157A1 (en) 2022-01-20
CN110612127B (zh) 2023-03-31
CN108853131A (zh) 2018-11-23
WO2018205978A1 (zh) 2018-11-15
US20200268785A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
Etzerodt et al. Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer
ES2705237T3 (es) Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón
Dai et al. Caffeic acid phenethyl ester prevents colitis-associated cancer by inhibiting NLRP3 inflammasome
Yang et al. Comparable molecular alterations in 4-nitroquinoline 1-oxide-induced oral and esophageal cancer in mice and in human esophageal cancer, associated with poor prognosis of patients
Wang et al. Exosome CTLA-4 regulates PTEN/CD44 signal pathway in spleen deficiency internal environment to promote invasion and metastasis of hepatocellular carcinoma
Zhu et al. microRNA-301b-3p from mesenchymal stem cells-derived extracellular vesicles inhibits TXNIP to promote multidrug resistance of gastric cancer cells
Meng et al. Cigarette smoke extracts induce overexpression of the proto-oncogenic gene interleukin-13 receptor α2 through activation of the PKA-CREB signaling pathway to trigger malignant transformation of lung vascular endothelial cells and angiogenesis
WO2020154207A1 (en) A novel method for monitoring and treating oral cancer
Jung et al. Abscisic acid regulates dormancy of prostate cancer disseminated tumor cells in the bone marrow
Liu et al. Tollip orchestrates macrophage polarization to alleviate intestinal mucosal inflammation
Merhi et al. The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update
Liu et al. High-calorie diet exacerbates prostate neoplasia in mice with haploinsufficiency of Pten tumor suppressor gene
Han et al. Bifidobacterium infantis maintains genome stability in ulcerative colitis via regulating anaphase-promoting complex subunit 7
US9199028B2 (en) Use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients
Tian et al. Exosomes derived from PC‑3 cells suppress osteoclast differentiation by downregulating miR‑148a and blocking the PI3K/AKT/mTOR pathway
CN110612127B (zh) 预防口腔癌的方法
Rahal et al. Dietary suppression of the mammary CD29hiCD24+ epithelial subpopulation and its cytokine/chemokine transcriptional signatures modifies mammary tumor risk in MMTV-Wnt1 transgenic mice
Xu et al. FOSL2 promotes intertumoral infiltration of T cells and increases pathological complete response rates in locally advanced rectal cancer patients
Zhang et al. Methionine enkephalin suppresses lung cancer metastasis by regulating the polarization of tumor-associated macrophages and the distribution of myeloid-derived suppressor cells in the tumor microenvironment and inhibiting epithelial-mesenchymal transition
Davidson Ovarian/primary peritoneal carcinoma
Brune et al. Loss of IRF5 increases ribosome biogenesis leading to alterations in mammary gland architecture and metastasis
Liu et al. Adenovirus‑mediated overexpression of interleukin‑21 regulates the development of oral squamous cell carcinoma in vitro
Chen et al. Axl as a potential therapeutic target for adamantinomatous craniopharyngiomas: based on single nucleus RNA-Seq and spatial transcriptome profiling.
Liu et al. Effect of WISP1 on paraquat-induced EMT
Cai Translational mechanisms of stem cell fate regulation in epidermal oncogene tolerance

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200714

Address after: 100050 No. 4, West Lane, Tiantan, Beijing, Dongcheng District

Applicant after: BEIJING STOMATOLOGICAL HOSPITAL, CAPITAL MEDICAL University

Address before: 102200 Room 101, four tower 11, Changping District science and Technology Park, Beijing.

Applicant before: BEIJING JIETENG BIOLOGICAL TECHNOLOGY Co.,Ltd.

GR01 Patent grant
GR01 Patent grant